Skip to content

Study · Animal study (in vivo) · rat and rhesus monkey · 2002

22 results

Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.

Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL

The Journal of pharmacology and experimental therapeutics1 Apr 2002Cited by 106 (Europe PMC)

PMID11907162 (opens in a new tab)DOI10.1124/jpet.301.1.95 (opens in a new tab)PepBankPUB-11907162
Publisher pagePubMedAsk about this study
Jump to 22 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study22

22 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, single degarelix injections produced dose-dependent decreases in plasma LH.

    In plain wordsIn rats, single degarelix injections reduced plasma LH in a dose-dependent manner.

    Peptide
    Degarelix
    Outcome
    DecreasePlasma LH
    Study

    ratn: not reported in source

    Rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.3 to 10 microg/kg · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    At single subcutaneous injections of 0.3 to 10 microg/kg in rats, degarelix produced a dose-dependent suppression of the pituitary-gonadal axis as revealed by the decrease in plasma luteinizing hormone (LH) and testosterone levels.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, single degarelix injections produced dose-dependent decreases in plasma testosterone.

    In plain wordsIn rats, single degarelix injections reduced plasma testosterone in a dose-dependent manner.

    Peptide
    Degarelix
    Outcome
    DecreasePlasma testosterone
    Study

    ratn: not reported in source

    Rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.3 to 10 microg/kg · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    At single subcutaneous injections of 0.3 to 10 microg/kg in rats, degarelix produced a dose-dependent suppression of the pituitary-gonadal axis as revealed by the decrease in plasma luteinizing hormone (LH) and testosterone levels.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, significant LH suppression lasted 1 day after a single degarelix injection at 12.5 microg/kg.

    In plain wordsIn rats, significant LH suppression lasted 1 day after degarelix at 12.5 microg/kg.

    Peptide
    Degarelix
    Outcome
    DecreaseLH suppression duration at 12.5 microg/kg
    Study

    ratn: not reported in source

    Rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    12.5 microg/kg · subcutaneous · Single injectionAs given in this study (rat).

    Source sentences

    Summary
    Duration of LH suppression increased with the dose: in the rat, significant suppression of LH lasted 1, 2, and 7 days after a single subcutaneous injection of degarelix at 12.5, 50, or 200 microg/kg, respectively.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, significant LH suppression lasted 2 days after a single degarelix injection at 50 microg/kg.

    In plain wordsIn rats, significant LH suppression lasted 2 days after degarelix at 50 microg/kg.

    Peptide
    Degarelix
    Outcome
    DecreaseLH suppression duration at 50 microg/kg
    Study

    ratn: not reported in source

    Rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    50 microg/kg · subcutaneous · Single injectionAs given in this study (rat).

    Source sentences

    Summary
    Duration of LH suppression increased with the dose: in the rat, significant suppression of LH lasted 1, 2, and 7 days after a single subcutaneous injection of degarelix at 12.5, 50, or 200 microg/kg, respectively.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats, significant LH suppression lasted 7 days after a single degarelix injection at 200 microg/kg.

    In plain wordsIn rats, significant LH suppression lasted 7 days after degarelix at 200 microg/kg.

    Peptide
    Degarelix
    Outcome
    DecreaseLH suppression duration at 200 microg/kg
    Study

    ratn: not reported in source

    Rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    200 microg/kg · subcutaneous · Single injectionAs given in this study (rat).

    Source sentences

    Summary
    Duration of LH suppression increased with the dose: in the rat, significant suppression of LH lasted 1, 2, and 7 days after a single subcutaneous injection of degarelix at 12.5, 50, or 200 microg/kg, respectively.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In castrated and intact rats, degarelix fully suppressed plasma LH for more than 40 days after a single injection.

    In plain wordsIn rats, degarelix fully suppressed plasma LH for more than 40 days after a single injection.

    Peptide
    Degarelix
    Outcome
    DecreasePlasma LH suppression in rats
    Study

    ratn: not reported in source

    Castrated and intact rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    2 mg/kg · subcutaneous · Single injectionAs given in this study (rat).

    Source sentences

    Summary
    Degarelix fully suppressed plasma LH and testosterone levels in the castrated and intact rats as well as in the ovariectomized rhesus monkey for more than 40 days after a single 2-mg/kg subcutaneous injection.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In castrated and intact rats, degarelix fully suppressed plasma testosterone for more than 40 days after a single injection.

    In plain wordsIn rats, degarelix fully suppressed plasma testosterone for more than 40 days after a single injection.

    Peptide
    Degarelix
    Outcome
    DecreasePlasma testosterone suppression in rats
    Study

    ratn: not reported in source

    Castrated and intact rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    2 mg/kg · subcutaneous · Single injectionAs given in this study (rat).

    Source sentences

    Summary
    Degarelix fully suppressed plasma LH and testosterone levels in the castrated and intact rats as well as in the ovariectomized rhesus monkey for more than 40 days after a single 2-mg/kg subcutaneous injection.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In an ovariectomized rhesus monkey, degarelix fully suppressed plasma LH for more than 40 days after a single injection.

    In plain wordsIn a rhesus monkey, degarelix fully suppressed plasma LH for more than 40 days after a single injection.

    Peptide
    Degarelix
    Outcome
    DecreasePlasma LH suppression in monkeys
    Study

    rhesus monkeyn: not reported in source

    Ovariectomized rhesus monkey
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    2 mg/kg · subcutaneous · Single injectionAs given in this study (rhesus monkey).

    Source sentences

    Summary
    Degarelix fully suppressed plasma LH and testosterone levels in the castrated and intact rats as well as in the ovariectomized rhesus monkey for more than 40 days after a single 2-mg/kg subcutaneous injection.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In an ovariectomized rhesus monkey, degarelix fully suppressed plasma testosterone for more than 40 days after a single injection.

    In plain wordsIn a rhesus monkey, degarelix fully suppressed plasma testosterone for more than 40 days after a single injection.

    Peptide
    Degarelix
    Outcome
    DecreasePlasma testosterone suppression in monkeys
    Study

    rhesus monkeyn: not reported in source

    Ovariectomized rhesus monkey
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    2 mg/kg · subcutaneous · Single injectionAs given in this study (rhesus monkey).

    Source sentences

    Summary
    Degarelix fully suppressed plasma LH and testosterone levels in the castrated and intact rats as well as in the ovariectomized rhesus monkey for more than 40 days after a single 2-mg/kg subcutaneous injection.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In comparative animal experiments, degarelix had a longer duration of action than abarelix.

    In plain wordsIn animals, degarelix acted longer than abarelix.

    Peptide
    Degarelix
    Outcome
    IncreaseDuration of action versus abarelix
    Study

    n: not reported in source

    Rats and monkeys
    Comparator
    Abarelix
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In comparative experiments, degarelix showed a longer duration of action than the recently developed GnRH antagonists abarelix, ganirelix, cetrorelix, and azaline B.
    1 context sentence
    Summary · context
    We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In comparative animal experiments, degarelix had a longer duration of action than ganirelix.

    In plain wordsIn animals, degarelix acted longer than ganirelix.

    Peptide
    Degarelix
    Outcome
    IncreaseDuration of action versus ganirelix
    Study

    n: not reported in source

    Rats and monkeys
    Comparator
    Ganirelix
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In comparative experiments, degarelix showed a longer duration of action than the recently developed GnRH antagonists abarelix, ganirelix, cetrorelix, and azaline B.
    1 context sentence
    Summary · context
    We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In comparative animal experiments, degarelix had a longer duration of action than cetrorelix.

    In plain wordsIn animals, degarelix acted longer than cetrorelix.

    Peptide
    Degarelix
    Outcome
    IncreaseDuration of action versus cetrorelix
    Study

    n: not reported in source

    Rats and monkeys
    Comparator
    Cetrorelix
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In comparative experiments, degarelix showed a longer duration of action than the recently developed GnRH antagonists abarelix, ganirelix, cetrorelix, and azaline B.
    1 context sentence
    Summary · context
    We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In comparative animal experiments, degarelix had a longer duration of action than azaline B.

    In plain wordsIn animals, degarelix acted longer than azaline B.

    Peptide
    Degarelix
    Outcome
    IncreaseDuration of action versus azaline B
    Study

    n: not reported in source

    Rats and monkeys
    Comparator
    Azaline B
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In comparative experiments, degarelix showed a longer duration of action than the recently developed GnRH antagonists abarelix, ganirelix, cetrorelix, and azaline B.
    1 context sentence
    Summary · context
    We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In comparative animal experiments, cetrorelix had a shorter duration of action than degarelix.

    In plain wordsIn animals, cetrorelix acted for less time than degarelix.

    Peptide
    Cetrorelix
    Outcome
    DecreaseDuration of action
    Study

    n: not reported in source

    Rats and monkeys
    Comparator
    Degarelix
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In comparative experiments, degarelix showed a longer duration of action than the recently developed GnRH antagonists abarelix, ganirelix, cetrorelix, and azaline B.
    1 context sentence
    Summary · context
    We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In comparative animal experiments, ganirelix had a shorter duration of action than degarelix.

    In plain wordsIn animals, ganirelix acted for less time than degarelix.

    Peptide
    Ganirelix
    Outcome
    DecreaseDuration of action
    Study

    n: not reported in source

    Rats and monkeys
    Comparator
    Degarelix
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In comparative experiments, degarelix showed a longer duration of action than the recently developed GnRH antagonists abarelix, ganirelix, cetrorelix, and azaline B.
    1 context sentence
    Summary · context
    We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists.
  16. 16AnimalAnimal study (in vivo)Mechanism

    In animals, the mechanism of degarelix was consistent with competitive antagonism.

    In plain wordsIn animals, degarelix acted in a way consistent with competitive antagonism.

    Peptide
    Degarelix
    Outcome
    Not applicableCompetitive antagonism
    Study

    n: not reported in source

    Rats and monkeys
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The in vivo mechanism of action of degarelix was consistent with competitive antagonism, and the prolonged action of degarelix was paralleled by continued presence of radioimmunoassayable degarelix in the general circulation.
    1 context sentence
    Summary · context
    We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists.
  17. 17AnimalAnimal study (in vivo)Pharmacokinetics

    In animals, prolonged degarelix action paralleled its continued presence in the circulation.

    In plain wordsIn animals, prolonged degarelix action coincided with its continued presence in the blood.

    Peptide
    Degarelix
    Outcome
    Not applicableCirculating degarelix persistence
    Study

    n: not reported in source

    Rats and monkeys
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The in vivo mechanism of action of degarelix was consistent with competitive antagonism, and the prolonged action of degarelix was paralleled by continued presence of radioimmunoassayable degarelix in the general circulation.
    1 context sentence
    Summary · context
    We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists.
  18. 18LabIn vitro (cells)Activity measurement

    In vitro, degarelix had weak histamine-releasing properties in contrast to cetrorelix.

    In plain wordsIn lab tests, degarelix released little histamine compared with cetrorelix.

    Peptide
    Degarelix
    Outcome
    DecreaseHistamine release versus cetrorelix
    Study

    n: not reported in source

    Comparator
    Cetrorelix
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast to cetrorelix and similarly to ganirelix and abarelix, degarelix had only weak histamine-releasing properties in vitro.
  19. 19LabIn vitro (cells)Activity measurement

    In vitro, cetrorelix had greater histamine-releasing properties than degarelix.

    In plain wordsIn lab tests, cetrorelix released more histamine than degarelix.

    Peptide
    Cetrorelix
    Outcome
    IncreaseHistamine release
    Study

    n: not reported in source

    Comparator
    Degarelix
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast to cetrorelix and similarly to ganirelix and abarelix, degarelix had only weak histamine-releasing properties in vitro.
  20. 20LabIn vitro (cells)Activity measurement

    In vitro, ganirelix had weak histamine-releasing properties similar to degarelix.

    In plain wordsIn lab tests, ganirelix released little histamine, similarly to degarelix.

    Peptide
    Ganirelix
    Outcome
    No significant changeHistamine release
    Study

    n: not reported in source

    Comparator
    Degarelix
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast to cetrorelix and similarly to ganirelix and abarelix, degarelix had only weak histamine-releasing properties in vitro.
  21. 21LabIn vitro (cells)Activity measurement

    In vitro, degarelix had weak histamine-releasing properties similar to ganirelix.

    In plain wordsIn lab tests, degarelix released little histamine, similarly to ganirelix.

    Peptide
    Degarelix
    Outcome
    No significant changeHistamine release versus ganirelix
    Study

    n: not reported in source

    Comparator
    Ganirelix
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast to cetrorelix and similarly to ganirelix and abarelix, degarelix had only weak histamine-releasing properties in vitro.
  22. 22LabIn vitro (cells)Activity measurement

    In vitro, degarelix had weak histamine-releasing properties similar to abarelix.

    In plain wordsIn lab tests, degarelix released little histamine, similarly to abarelix.

    Peptide
    Degarelix
    Outcome
    No significant changeHistamine release versus abarelix
    Study

    n: not reported in source

    Comparator
    Abarelix
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast to cetrorelix and similarly to ganirelix and abarelix, degarelix had only weak histamine-releasing properties in vitro.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Versions 2 to 3

    27 Oct 2026, 16:35 UTC

    The same notice was added 2 times, first on 27 Oct 2026, 16:35 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.